(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
03 March 2022 (03.03.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/043227 A1

(51) International Patent Classification:
A61K 31/4045 (2006.01) *A61K 9/08* (2006.01)
A61P 25/22 (2006.01) *A61K 9/00* (2006.01)
A61K 47/12 (2006.01)

(21) International Application Number:
PCT/EP2021/073189

(22) International Filing Date:
20 August 2021 (20.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2013571.1 28 August 2020 (28.08.2020) GB
17/006,115 28 August 2020 (28.08.2020) US

(71) Applicant: **SMALL PHARMA LTD** [GB/GB]; 6-8 Bonhill St, London Greater London EC2A 4BX (GB).

(72) Inventors: **LAYZELL, Marie Claire**; C/o Small Pharma Ltd, 6-8 Bonhill Street, London EC2A 4BX (GB). **RENNIE, James Maxwell**; C/o Small Pharma Ltd, 6-8 Bonhill Street, London EC2A 4BX (GB).

(74) Agent: **PATENT BOUTIQUE LLP**; 10A Printing House Yard, Hackney Road, London E2 7PR (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to the identity of the inventor (Rule 4.17(i))*
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2022/043227 A1

(54) Title: INJECTABLE FORMULATION

(57) Abstract: Provided herein are pharmaceutical formulations, methods for their production, and uses thereof. The pharmaceutical formulations comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, which is separate to the salt, and water. The formulations have pH values of from about 3.5 to about 6.5 and osmolalities of about 250 to about 350 mOsm/Kg. Such formulations are optionally suitable for injection, being both stable and clinically acceptable, and have potential uses in the treatment of psychiatric or neurological disorders.